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MA, USA, 3RTI International, Research Triangle Park, NC, USA, 4CDC, Atlanta, GA, USA
OBJECTIVES: To date, no study has reported on the cost of treating breast and cervi-
cal cancer among Medicaid beneﬁciaries younger than 65 years of age. This study 
estimates the incremental cost of breast and cervical cancer care among Medicaid 
beneﬁciaries under age 65. METHODS: Administrative data from the North Carolina 
(NC) Medicaid program linked with the state’s central cancer registry data from 
2002–2004 were used to analyze total Medicaid costs for medically underserved low-
income women aged <65 years diagnosed with breast and cervical cancer who are 
eligible for the Medicaid program and the incremental costs for breast and cervical 
cancer care at 6, 12, and 24 months from diagnosis. We used a two-part regression 
model to estimate the impact of breast and cervical cancer by stage at diagnosis on 
total Medicaid expenditures from time of diagnosis through 6, 12, and 24 months. 
All analyses were completed using SAS. RESULTS: The total incremental Medicaid 
costs (standard error) of treating breast cancer relative to no cancer at 6 months after 
diagnosis were $11,350 ($760), $20,227 ($1,146), and $28,911 ($3,422) for those 
with local, regional and distant cancers, respectively. These costs increased 33.0%, 
43.7%, and 50.6% at 12 months; and 39.3, 45.4, and 73.6% at 24 months, respect-
fully. For cervical cancer, these costs were $11,995 ($2,043) and $20,753 ($2,299) 
for local and regional cancers. These costs increased 30.4 and 18.6% at 12 months. 
As expected, women whose cancers were detected at a local stage incurred lower 
medical expenses compared with women with invasive cancers. CONCLUSIONS: Our 
study shows that NC Medicaid beneﬁciaries with late stage cancers incurred higher 
medical costs that persisted for 12 months or longer after the date of diagnosis. 
Improved early detection of breast and cervical cancer among low-income women 
could potentially reduce the ﬁnancial burden to the Medicaid program.
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A SUCCESSFUL ADOPTION OF PERSONALIZED MEDICINE: EXAMPLE 
OF KRAS MUTATIONAL ANALYSIS
Wang G, Van Bebber S, Phillips K
University of California, San Francisco, San Francisco, CA, USA
OBJECTIVES: This study examines KRAS mutational analysis in metastatic colorectal 
cancer as an example of a successfully adopted personalized medicine technology. 
Objectives are to describe factors involved in the adoption of KRAS mutational analy-
sis and to examine relationships between factors over time. METHODS: We used a 
framework called the Evaluation Data for Assessing Personalized Medicine’s Transla-
tion (EDAPT) to collect and organize data on KRAS mutational analysis. EDAPT 
focuses on collecting data on clinical application, economic, policy and regulatory 
issues using structured reviews of academic and gray literature. We used Innovation-
Decision Theory to analyze how factors emerged over time and relationships between 
factors. RESULTS: Initial studies suggesting association between KRAS status and 
drug efﬁcacy led to industry-supported retrospective analyses of RCT data. After 
assessing evidence via systematic review, National Comprehensive Cancer Network 
and American Society of Clinical Oncology signaled acceptance of KRAS mutational 
analysis by issuing clinical guidelines, thereby making KRAS mutational analysis 
standard of care. The clinical guidelines were inﬂuential in implementation of payer 
coverage policies and discussions at the FDA about retrospective data. We detect a 
pattern: 1) Retrospective analyses of RCT data increased knowledge of the technology 
among stakeholders; 2) A systematic review of evidence concluded that evidence sur-
rounding the technology was robust; 3) Persuaded by the review’s conclusion, provider 
organizations decided to accept the technology and communicated this decision 
through clinical guidelines; 4) Clinical guidelines inﬂuenced payer policies, which 
framed the implementation of the technology into health care. Provider organization 
decisions swayed regulatory agents’ recognition of these retrospective analyses, 
thereby conﬁrming acceptance of the technology. CONCLUSIONS: This example 
illustrates how evidence of clinical utility and provider organization support can drive 
rapid adoption. We propose an application of the Innovation-Decision Theory that 
may help to anticipate future trends in personalized medicine.
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THE ECONOMIC IMPACT OF CONTOUR VERSUS HAND SEWN SUTURE 
AND OTHER MECHANICAL STAPLES IN LOW ANTERIOR RESECTIONS 
IN COLON RECTAL CANCER SURGERY: INTERIM RESULTS USING REAL 
WORLD DATA FROM PREMIER’S HOSPITAL DATABASE
Nasciben V1, Rupprecht F2, Moore M3, Gunnarsson C4
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OBJECTIVES: The CONTOUR® Curved Cutter Stapler is designed to allow for 
increased visibility of anatomic structures. As a result, it is currently being used for 
colon rectal procedures where Low Anterior Resection (LAR) is necessary. To assess 
the impact this technology is having on hospital costs, length of stay, and surgery time, 
this research compares the contour stapler to traditional sutures and to other staplers 
for colon rectal procedures where Low Anterior Resection (LAR) is being performed. 
METHODS: A retrospective analysis was completed using Premier’s de-identiﬁed 
hospital database and enrollment information for the fourth quarter of 2008. Multi-
variable analysis evaluated the effect of the contour stapler vs. traditional sutures and 
the contour stapler vs. other staplers on hospital costs, length of stay, and surgery 
time while controlling for patient severity. This abstract reports preliminary ﬁndings. 
RESULTS: There were a total of 3544 procedures meeting the inclusion criteria; 195 
were identiﬁed, through patient billing ﬁles, as using the Contour stapler, 41 proce-
dures were identiﬁed as traditional sutures only and the remaining 3,308 reported the 
use of another stapling device. When comparing the Contour patients to the suture 
only patients, and the other stapler patients, on average hospital costs were as follows: 
Contour ($23,742.52) traditional sutures ($24,547.66) and other staplers 
($24,845.59). Multivariable ﬁndings for Contour vs. traditional sutures were statisti-
cally signiﬁcant for hospital costs with the interaction between contour vs. traditional 
sutures and patient severity being statistically signiﬁcant. These ﬁndings suggest that 
the more severe patients will have higher hospital costs with traditional sutures than 
they will with Contour. Length of stay and surgery time were not statistically signiﬁ-
cant for either comparison. CONCLUSIONS: Contour appears to be cost saving when 
compared to traditional sutures, especially when the case is severe and cost neutral 
when compared to other staplers.
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CONTROLLING THE COST OF CARE OF BREAST CANCER PATIENTS 
IN GERMANY USING CLINICAL PATHWAYS
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OBJECTIVES: In Germany, development of clinical pathways in routine health care 
settings is a slow process. Our main objectives were: 1) to introduce proper clinical 
pathways of breast cancer (BC) management in a large hospital in Munich, Germany, 
2) to identify problems in the implementation process of clinical pathways, and 3) to 
suggest steps for further improvement of clinical pathway strategies. METHODS: In 
collaboration with health care professionals (HCPs) working in a large Munich hos-
pital, we developed a clinical pathway algorithm for management of BC patients and 
introduced it to that hospital for implementation. Then we developed a standardized 
checklist to measure the success of the clinical pathways program based on various 
clinical indicators, reported by HCPs involved in BC management. And ﬁnally, we 
compared health economics data of two groups of patients with primary diagnosis of 
BC: intervention group (n = 45), which was managed according to our clinical 
pathway in 2004, and comparator group (n = 56), which was managed in 2003 prior 
to introduction of clinical pathways. RESULTS: Mean duration of hospitalization in 
intervention group was slightly higher compared to comparator group (9.08 vs. 8.75, 
respectively), but approximately 51% of patients in intervention group were dis-
charged from the hospital within 7–8 days compared to 40% in comparator group. 
About 73% of patients in intervention group have been admitted 1 day prior to 
operative treatment, compared to 93% of patients in comparator group. By means of 
a survey we learned, that only a small percentage (up to 17%) of HCPs in that hospital 
were aware of the detailed processes of clinical pathways. CONCLUSIONS: Clinical 
pathways are important tools in that they optimize health care processes and can 
potentially lead to cost savings through optimal care. However, proper training and 
active involvement of HCPs in the implementation of clinical pathway processes is 
important.
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THE IMPACT OF PROSTATE CANCER AMONG CAUCASIAN AND 
AFRICAN AMERICANS IN A HOSPITALIZED SETTING
Atkins E, Halverson J
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OBJECTIVES: Prostate cancer is the second most common cause of death from cancer 
in men of all ages and the most common cause of death from cancer in men over 75 
years old. The mortality rates in African-American men are more than twice that of 
Caucasian men, even after attempts to adjust for access-to-care factors. Even with 
increases in screening, African American men still experience high incidence and 
mortality rates than all races. Therefore, the speciﬁc aim was to examine differences 
affecting Caucasian and African American men with prostate cancer in a hospitalized 
setting. METHODS: The study design was an exploratory, nonrandomized, secondary 
data analysis of the 2006 HCUP—NIS. Ten percent of the subsample was used. Only 
Caucasian and African American men with a primary diagnosis of prostate cancer 
(ICD-9 Code = 185) were included. SPSS 15.0 was used to analyze the data. RESULTS: 
The study population consisted of 9,736 Caucasian Americans (87.5%) and 1,387 
African Americans (12.5%). Results of the t-test (p = .000) indicated that Caucasian 
Americans experienced a signiﬁcantly lower average length of stay than African 
Americans (3.04 vs 5.04 days, respectively). Based on the regression analysis, the 
model was signiﬁcant (F = 520.746, p = .000; R2 = 27.6%). Six of the eight variables 
were signiﬁcant; race, income, admission source, principal procedure, length of stay, 
and died during hospitalization, each with a p = .000 value. The mean for total charges 
was $24,293, with a standard deviation of $23,339. CONCLUSIONS: Differences 
were found among the two groups. These ﬁndings may assist health care entities in 
determining additional factors which could aid in the ﬁght against prostate cancer. In 
addition, private payers (including HMOs and Medicare) would especially be inter-
ested since each entity represented the bulk of expected primary payers for the hospi-
talized patients.
